Senseonics (NYSE:SENS) Stock Price Down 4% – Time to Sell?

by · The Markets Daily

Senseonics Holdings, Inc. (NYSE:SENS – Get Free Report) fell 4% during trading on Friday . The company traded as low as $0.81 and last traded at $0.84. 7,077,628 shares were traded during mid-day trading, a decline of 71% from the average session volume of 24,212,734 shares. The stock had previously closed at $0.88.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on SENS shares. HC Wainwright reiterated a “buy” rating and set a $2.00 target price on shares of Senseonics in a research note on Friday, November 15th. StockNews.com began coverage on Senseonics in a report on Thursday, December 26th. They set a “sell” rating for the company.

Read Our Latest Research Report on SENS

Senseonics Trading Down 3.9 %

The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. The company’s fifty day moving average price is $0.42 and its two-hundred day moving average price is $0.40. The firm has a market cap of $500.67 million, a PE ratio of -6.47 and a beta of 0.64.

Insider Activity at Senseonics

In related news, CFO Frederick T. Sullivan bought 124,933 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the transaction, the chief financial officer now owns 2,478,844 shares of the company’s stock, valued at approximately $941,960.72. This trade represents a 5.31 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Timothy T. Goodnow acquired 315,000 shares of Senseonics stock in a transaction that occurred on Tuesday, December 10th. The stock was bought at an average price of $0.31 per share, with a total value of $97,650.00. Following the purchase, the chief executive officer now directly owns 11,310,355 shares of the company’s stock, valued at approximately $3,506,210.05. This trade represents a 2.86 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Senseonics

Several hedge funds have recently added to or reduced their stakes in SENS. FMR LLC lifted its position in shares of Senseonics by 48,267.2% in the third quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after acquiring an additional 167,970 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Senseonics during the 3rd quarter worth about $117,000. Cubist Systematic Strategies LLC grew its holdings in shares of Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after buying an additional 85,501 shares in the last quarter. Symmetry Partners LLC acquired a new position in shares of Senseonics in the third quarter valued at approximately $164,000. Finally, Geode Capital Management LLC lifted its stake in shares of Senseonics by 3.2% during the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after buying an additional 179,103 shares during the period. 12.36% of the stock is currently owned by hedge funds and other institutional investors.

About Senseonics

(Get Free Report)

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.

See Also